Cargando…

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

The introduction of biological therapies into clinical practice has dramatically modified the natural history of chronic inflammatory diseases, such as rheumatoid arthritis (RA). RA is a systemic autoimmune disease that causes articular damage and has a great negative impact on patients’ quality of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crotti, Chiara, Raimondo, Maria Gabriella, Becciolini, Andrea, Biggioggero, Martina, Favalli, Ennio Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245809/ https://www.ncbi.nlm.nih.gov/pubmed/28144129 http://dx.doi.org/10.2147/DDDT.S104233

Ejemplares similares

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
por: Favalli, Ennio Giulio, et al.
Publicado: (2018)

Structural integrity versus radiographic progression in rheumatoid arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2015)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
por: Biggioggero, Martina, et al.
Publicado: (2018)

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
por: Favalli, Ennio Giulio, et al.
Publicado: (2014)

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
por: Di Franco, Manuela, et al.
Publicado: (2014)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
por: Biggioggero, Martina, et al.
Publicado: (2019)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
por: Favalli, Ennio Giulio, et al.
Publicado: (2023)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

COVID-19 infection and rheumatoid arthritis: Faraway, so close!
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
por: Levin, Pavel A, et al.
Publicado: (2017)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
por: Favalli, Ennio G.
Publicado: (2020)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2016)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9dc7fqtr8eboki0sajhjfrf88i